Live attenuated influenza virus vaccines by computer-aided rational design

Abstract

Despite existing vaccines and enormous efforts in biomedical research, influenza annually claims 250,000–500,000 lives worldwide1, motivating the search for new, more effective vaccines that can be rapidly designed and easily produced. We applied the previously described synthetic attenuated virus engineering (SAVE)2 approach to influenza virus strain A/PR/8/34 to rationally design live attenuated influenza virus vaccine candidates through genome-scale changes in codon-pair bias. As attenuation is based on many hundreds of nucleotide changes across the viral genome, reversion of the attenuated variant to a virulent form is unlikely. Immunization of mice by a single intranasal exposure to codon pair–deoptimized virus conferred protection against subsequent challenge with wild-type (WT) influenza virus. The method can be applied rapidly to any emerging influenza virus in its entirety, an advantage that is especially relevant when dealing with seasonal epidemics and pandemic threats, such as H5N1- or 2009-H1N1 influenza.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Characterization in tissue culture of synthetic codon pair–deoptimized influenza viruses.
Figure 2: Attenuation of codon pair–deoptimized influenza virus PR83F in BALB/c mice.
Figure 3: Immune responses and protection.

Accession codes

Accessions

NCBI Reference Sequence

References

  1. 1

    Salomon, R. & Webster, R.G. The influenza virus enigma. Cell 136, 402–410 (2009).

  2. 2

    Coleman, J.R. et al. Virus attenuation by genome-scale changes in codon-pair bias. Science 320, 1784–1787 (2008).

  3. 3

    Palese, P. & Shaw, M.L. in Field's Virology, vol. 2 (eds. D.M. Knipe et al.) 1647–1689, (Lippincott Williams & Wilkins, Philadelphia, 2007).

  4. 4

    Steinhauer, D.A. & Skehel, J.J. Genetics of influenza viruses. Annu. Rev. Genet. 36, 305–332 (2002).

  5. 5

    Maassab, H.F. Adaptation and growth characteristics of influenza virus at 25 degrees c. Nature 213, 612–614 (1967).

  6. 6

    Rimmelzwaan, G.F., Fouchier, R.A. & Osterhaus, A.D. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18, 529–536 (2007).

  7. 7

    Sant, A.J. et al. Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev. Vaccines 6, 357–368 (2007).

  8. 8

    Hikono, H. et al. T-cell memory and recall responses to respiratory virus infections. Immunol. Rev. 211, 119–132 (2006).

  9. 9

    Swain, S.L. et al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol. Rev. 211, 8–22 (2006).

  10. 10

    Simonsen, L. et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch. Intern. Med. 165, 265–272 (2005).

  11. 11

    Belshe, R.B., Van Voris, L.P., Bartram, J. & Crookshanks, F.K. Live attenuated influenza A virus vaccines in children: results of a field trial. J. Infect. Dis. 150, 834–840 (1984).

  12. 12

    Belshe, R.B. et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338, 1405–1412 (1998).

  13. 13

    Cello, J., Paul, A.V. & Wimmer, E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 297, 1016–1018 (2002).

  14. 14

    Gutman, G.A. & Hatfield, G.W. Nonrandom utilization of codon pairs in Escherichia coli. Proc. Natl. Acad. Sci. USA 86, 3699–3703 (1989).

  15. 15

    Moura, G. et al. Large scale comparative codon-pair context analysis unveils general rules that fine-tune evolution of mRNA primary structure. PLoS ONE 2, e847 (2007).

  16. 16

    Wimmer, E., Mueller, S., Tumpey, T.M. & Taubenberger, J.K. Synthetic viruses: a new opportunity to understand and prevent viral disease. Nat. Biotechnol. 27, 1163–1172 (2009).

  17. 17

    Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R.G.A. DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 97, 6108–6113 (2000).

  18. 18

    Schickli, J.H. et al. Plasmid-only rescue of influenza A virus vaccine candidates. Phil. Trans. R. Soc. Lond. B 356, 1965–1973 (2001).

  19. 19

    Mueller, S., Papamichail, D., Coleman, J.R., Skiena, S. & Wimmer, E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80, 9687–9696 (2006).

  20. 20

    Shizhen, L . Compendium of Materia Medica (Bencao Gangmu, 1593) (Foreign Language Press, 2004).

  21. 21

    Hutchinson, E.C., Curran, M.D., Read, E.K., Gog, J.R. & Digard, P. Mutational analysis of cis-acting RNA signals in segment 7 of influenza A virus. J. Virol. 82, 11869–11879 (2008).

  22. 22

    Wang, Z., Tobler, S., Roayaei, J. & Eick, A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. J. Am. Med. Assoc. 301, 945–953 (2009).

  23. 23

    Coffin, J.M. Attenuation by a thousand cuts. N. Engl. J. Med. 359, 2283–2285 (2008).

  24. 24

    Reed, L.J. & Muench, M. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27, 493–497 (1938).

  25. 25

    Quinlivan, M. et al. Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 79, 8431–8439 (2005).

Download references

Acknowledgements

The authors are indebted to A. García-Sastre and P. Palese for sharing with us their 8-plasmid system for PR8, antibodies, and information. We thank A. Paul and J. Cello for comments on the manuscript. Supported by National Institutes of Health grants AI075219 and AI15122 (EW) and a TRO-Fusion Award by Stony Brook University (S.M. and S.S.).

Author information

S.M. designed and carried out the majority of the study and wrote the paper. J.R.C. and A.N. carried out experiments contributing to Figures 1c and 2. D.P., C.B.W. and S.S. developed computer design and analysis algorithms. B.F. and E.W. contributed to the design of the study and writing of the paper.

Correspondence to Steffen Mueller.

Ethics declarations

Competing interests

All authors declare they have a patent pending relating to certain aspects of this work.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–3 (PDF 322 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mueller, S., Coleman, J., Papamichail, D. et al. Live attenuated influenza virus vaccines by computer-aided rational design. Nat Biotechnol 28, 723–726 (2010) doi:10.1038/nbt.1636

Download citation

Further reading